Cryopreservation of human preimplantation embryos from the in vitro fertilization program (IVF) is nowadays a routine practice in most IVF laboratories. The slow embryo freezing method began to be clinically used in 1985, with the introduction of specific cryoprotectants and computer-controlled freezers, which enabled the controlled cooling of embryos down to -7 °C, when ice nucleation (seeding) was induced in the surrounding cryoprotective medium1. By continuous cooling, the ice crystals would grow, causing the hyperosmolality of the remaining liquid fraction and, consequently, the dehydration and shrinkage of the embryonic cells. At -30 °C or -80 °C, the embryos would be plunged into the liquid nitrogen for longer storage. What was happening with the embryos or oocytes during cooling could be observed only by specially adapted cryomicroscopes, which helped to improve cryopreservation protocols2. The freezing of blastocysts, a higher-volume and more fluid-contained embryonic stage, gave less promising clinical results in those days3.
The breakthrough in the cryopreservation of the blastocyst was the introduction of the vitrification method, in which the dehydration of the cells took place before cooling by using high concentrations of cryoprotectants4. The removal of the fluid from the blastocoel before vitrification can also be achieved by making a mechanical opening between two trophectoderm cells5. Although the immediate blastocyst survival rate after vitrification and warming is above 90%, and the clinical outcome following the transfer of vitrified/warmed blastocyst into the uterine cavity is almost comparable to results after the transfer of fresh embryos, this cryopreservation method has not yet been standardized6,7. Vitrification protocols vary according to (a) the type and concentration of the cryoprotectants, (b) the number of previtrification steps, (c) the duration of individual steps, (d) the use of an artificial blastocoel collapsing before vitrification or not, (e) collapsing methods, (f) the blastocyst expansion stage, and (g) the equilibration/vitrification temperature at which the embryos should be vitrified8. Since cryoprotectants can be toxic for cells, the blastocyst exposure time to these solutions has to be well defined. However, some cryopreservation media manufacturers allow very flexible protocols.
The interest of scientists is usually focused on studying the blastocyst re-expansion ability with the aim to find new biomarkers with a better prediction of implantation6,9,10. How human blastocysts dehydrate at different steps of adding cryoprotectants before vitrification and what happens with blastocysts after vitrification and warming, when cryoprotectants have to be removed from the cells, and how the blastocysts rehydrate and re-expand after warming, is not well described nor understood. The development of a methodology for the objective and quantified monitoring of blastocyst behavior during different cryopreservation steps is, thus, rationale.
With time-lapse microscopes of various manufacturers, it is now possible to monitor the behavior of the blastocyst in pre- and post-vitrification phases. By including additional computer tools, measurements of their size (morphometry) can also be performed. By measuring the decrease or increase in embryo size at a given time, it is possible to objectify the evaluation of morphodynamics of embryos during dehydration and rehydration.